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The scale-up of malaria control efforts has led to marked reductions in malaria burden over
the past twenty years, but progress has slowed. Implementation of indoor residual spraying
(IRS) of insecticide, a proven vector control intervention, has been limited and difficult
to sustain partly because questions remain on its added impact over widely accepted
interventions such as bed nets. Using data from 14 enhanced surveillance health facilities in
Uganda, a country with high bed net coverage yet high malaria burden, we estimate the
impact of starting and stopping IRS on changes in malaria incidence. We show that stopping
IRS was associated with a 5-fold increase in malaria incidence within 10 months, but rein-
stating IRS was associated with an over 5-fold decrease within 8 months. In areas where IRS
was initiated and sustained, malaria incidence dropped by 85% after year 4. IRS could play a
critical role in achieving global malaria targets, particularly in areas where progress has
stalled.
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Over the past 20 years the scale-up of malaria controlefforts has led to marked reductions in morbidity andmortality1,2. However, global progress has slowed in
recent years, particularly in sub-Saharan Africa, which accounted
for 94% of the world’s 215 million cases in 20192. Long-lasting
insecticidal nets (LLINs) and indoor residual spraying (IRS) of
insecticide are the primary vector control interventions used for
the prevention of malaria. The World Health Organization
recommends universal coverage of LLINs for at-risk populations
in sub-Saharan Africa, where the proportion of households
owning at least one LLIN is estimated to have increased from
47% in 2010 to 72% in 2018. Pyrethroids are the only class of
insecticides widely use in LLINs and, given the emergence of
widespread pyrethroid resistance3,4, there is concern that the
effectiveness of LLINs may be diminishing, leading to the
development of new LLIN formulations including pyrethroid
synergists and non-pyrethroid nets. Unlike LLINs, IRS has the
advantage of utilizing multiple different classes of insecticides and
combining IRS with LLINs may improve malaria control and
slow the spread of pyrethroid resistance. However, few controlled
trials have evaluated the effect of adding IRS to communities
using LLINs and the evidence is mixed, with a few studies
showing benefits when IRS included “non-pyrethroid-like”
insecticides5. Other barriers to IRS delivery—including cost,
logistics, and community acceptance—have limited its use6, such
that less than 2% of the population at risk in sub-Saharan Africa
was protected by IRS in 2019, a decrease from over 10% coverage
in 20102.
Uganda is illustrative of a country where the burden of malaria
remains high and progress has slowed in recent years2. Malaria
control efforts in Uganda have primarily focused on LLINs. In
2013–14 it became the first country to implement a universal
LLIN distribution campaign, which was repeated in 2017–18. In
2018–19, Uganda had the highest coverage of LLINs in the world,
with 83% of households reporting owning at least one LLIN7. In
contrast to LLINs, the implementation of IRS in Uganda has been
focal and limited. In 2006, IRS was reintroduced into Uganda for
the first time since the 1960s. In 2007–09, the IRS program was
shifted to ten high burden districts in the north, leading to large
reductions in malaria burden8,9. In 2014, the IRS program was
relocated from these ten northern districts to 14 districts in the
eastern part of the country, where it has been sustained. The
discontinuation of IRS in the ten northern districts was followed
by a marked resurgence in malaria cases10,11, prompting the
implementation of a single round of IRS in these ten districts
in 2017.
In this study, we use data from a network of health facility-
based malaria surveillance sites to evaluate the impact of different
IRS delivery scenarios in 14 districts in Uganda. This study has
three objectives: (1) to estimate the impact of withdrawing IRS
after 5 years of sustained use on the burden of malaria in three
sites in Northern Uganda; (2) to estimate the impact of restarting
IRS with a single round 3 to 4 years after IRS was discontinued on
the burden of malaria in nine sites in Northern Uganda; and (3)
to estimate the impact of 5 years of sustained IRS on the burden
of malaria in five sites in Northern and Eastern Uganda.
Results
Study sites and vector control interventions. This study utilized
data from 14 health facilities located in 14 districts in Northern
and Eastern Uganda (Fig. 1) which were part of a larger com-
prehensive malaria surveillance network called the Uganda
Malaria Surveillance Program (UMSP). Between 2007 and 2009,
IRS was implemented in ten high burden districts in northern
Uganda12. DDT or pyrethroids were initially used but in 2010 the
insecticide was changed to a carbamate (bendiocarb) due to
concern regarding the spread of pyrethroid resistance. Rounds of
bendiocarb were repeated approximately every 6 months until
2014 when the IRS program was discontinued, so that resources
could be shifted to other high burden districts. In 2017, these ten
districts in northern Uganda received a single round of the
organophosphate pirimiphos-methyl (Actellic 300CS®) following
reports of malaria resurgence after IRS has been discontinued in
2014. Between 2014 and 2015, IRS with bendiocarb was imple-
mented in 14 districts in the Northern and Eastern part of the
country. Rounds of bendiocarb were repeated approximately
every 6 months until 2016 when the formulation was changed to
Actellic 300CS®, which continues to be administered once a year.
Universal LLIN distribution campaigns were conducted in
2013–14 and 2017–18, where LLINs were distributed free-of-
charge by the Uganda Ministry of Health targeting one LLIN for
every two household residents. In 2013–14, all districts across the
country received LLINs impregnated with pyrethroid insecticides.
In 2017–18, the Ministry of Health distributed both conventional
LLINs and LLINs containing piperonyl butoxide (PBO) due to
concerns of pyrethroid resistance. During the latter distribution,
all districts included in this analysis received conventional
pyrethroid insecticides due to prior concerns of antagonism
between PBO LLINs and Actellic 300CS®.13
We assessed the impact of stopping IRS after sustained use
(objective 1), reinitiating IRS for a single round after stopping 3
years prior (objective 2), and initiating and sustaining IRS in areas
that had not received the intervention prior (objective 3) on
changes in malaria case counts relative to a baseline before to
starting or stopping IRS. Figure 2 shows the timeline of control
interventions and study timelines (with more detail for each site
in Supplementary Fig. 1).
Impact of withdrawing IRS after sustained use. Across the three
sites included in the analysis, a total of 224,859 outpatient visits
were observed (Table 1). During the baseline period, average
monthly cases ranged from 104–272 and test positivity rate
(TPR), the proportion of individuals tested for malaria that
resulted in a positive test, ranged from 23.7–25.9%. This increased
to 491–751 and 52.3–78.0% respectively, during the evaluation
period (Supplementary Fig. 2).
Monthly adjusted IRRs and 95% confidence intervals (CI)
for the three sites combined are presented in Fig. 3 and
Supplementary Table 1. These results showed an initial reduction
in malaria cases after the final round of IRS relative to the baseline
period until (adjusted IRR in the first month after IRS= 0.19, 95%
CI 0.09–0.42) about 4 to 5 months after the final IRS campaign
when malaria cases began to increase. Over the 10–31 months
after IRS was stopped, the number of malaria cases increased by
over fivefold relative to the baseline period (adjusted IRR= 5.24,
95% CI 3.67–7.50). This corresponds to predicted case counts of
near zero immediately following final IRS campaign followed by
an increase to about 1000 cases per month at each site (Fig. 3).
These results were consistent when considering only laboratory-
confirmed cases unadjusted for testing rates (Supplementary
Fig. 3).
Impact of restarting IRS with a single round. A total of 858,380
outpatient visits were recorded across the analysis period for the
nine sites (Table 2). Mean monthly malaria cases ranged from
643–1569 and the TPR ranged from 56.5–84.7% during the
baseline period. These ranges were 501–762 and 48.5–72.0%,
respectively during the evaluation period. Temporal trends of
laboratory-confirmed malaria cases over time for the individual
health facilities are presented in Supplementary Fig. 4.
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Monthly adjusted IRRs and 95% CI for the nine sites combined
are presented in Fig. 4 and Supplementary Table 2. The single
round of IRS was associated with a reduction in malaria cases
until ~23 months post-IRS. Over the 8–12 months after the single
round of IRS, malaria cases decreased by over fivefold relative to
the baseline period (adjusted IRR= 0.17, 95% CI 0.15–0.20).
After 23 months following the single round of IRS, malaria cases
returned to a level similar to the baseline period before the single
round of IRS (adjusted IRR for months 23–31= 1.06, 95% CI
0.92–1.21). These results were consistent when considering only
laboratory-confirmed cases unadjusted for testing rates (Supple-
mentary Fig. 5).
Impact of initiating and sustaining IRS. In total, 574,587 out-
patient visits were observed across the five sites included in the
analysis (Table 3). During the baseline period, average monthly
Fig. 2 Timeline summarizing the dates of indoor residual spraying (IRS) campaigns, baseline, and evaluation periods. Objective 1 is to assess the impact of
withdrawing IRS after 5 years of sustained use; Objective 2 is to assess the impact of restarting IRS with a single round; and Objective 3 is to assess the
impact of initiating and sustaining IRS. Exact dates of interventions are general; details on intervention dates by site are shown in Supplementary Fig. 1.
Fig. 1 Map of Uganda showing study sites (Malaria Reference Centers) and indoor residual spraying (IRS) districts. Districts not included in the analysis
did not have an active Malaria Reference Center during the study period. Objective 1 is to assess the impact of withdrawing IRS after 5 years of sustained use;
Objective 2 is to assess the impact of restarting IRS with a single round; and Objective 3 is to assess the impact of initiating and sustaining IRS.
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malaria cases adjusted for testing rates ranged from 286–657 and
the TPR ranged from 25.4–67.0%. This range decreased to 85–289
for malaria cases and 13.8–45.3% for the TPR during the eva-
luation period. Temporal trends of laboratory-confirmed malaria
cases over time for the individual health facilities are presented in
Supplementary Fig. 6.
Monthly adjusted IRRs and 95% CI for the five sites combined
are presented in Fig. 5 and Supplementary Table 3. There was a
modest overall reduction in malaria case counts in the first 3
years after IRS was initiated relative to the baseline period, with
some peaks in case counts returning to near baseline levels just
prior to when rounds of IRS were administered. However, after
the third year of sustained use, malaria case counts dropped
substantially and remained low relative to the period before IRS
was initiated. In the fourth and fifth year after IRS was initiated
and sustained, malaria cases dropped by 85% (adjusted IRR=
0.15, 95% CI 0.12–0.18). These results were consistent when
considering only laboratory-confirmed cases unadjusted for
testing rates (Supplementary Fig. 7).
Discussion
Uganda has been exceptionally successful in scaling-up coverage
of LLINs. Following the mass distribution campaigns to deliver
free LLINs in 2013–14 and 2017–18, 90 and 83% of households,
respectively reported ownership of at least one LLIN7,14. How-
ever, despite this success, the burden of malaria remains high in
much of the country. Uganda had the third highest number of
malaria cases reported in 2019, with reported case incidence
increasing since 20142. If Uganda is to achieve the goals estab-
lished by the World Health Organization’s Global Technical
Strategy for malaria including reducing malaria case incidence by
at least 90% by 2030 as compared with 201515, additional malaria
control measures will be needed. This report highlights the cri-
tical role of IRS in substantially reducing the burden of malaria in
areas where transmission remains high despite deployment of
LLINs. Withdrawing IRS after 5 years of sustained use in three
districts in northern Uganda was associated with a more than
fivefold increase in malaria cases within 10 months. Restarting
IRS with a single round in nine districts in Northern Uganda ~3
years after IRS had been stopped was associated with a transient
but important (more than a fivefold) decrease in malaria cases
within 8–12 months, returning to pre-IRS levels after 23 months.
Initiating and sustaining IRS in five districts in Eastern Uganda
was associated with a gradual reduction in malaria cases reaching
almost a sevenfold reduction after 4–5 years.
Robust evidence supports the widespread use of LLINs for
malaria control. In a systematic review of clinical trials conducted
between 1987 and 2001, insecticide treated nets reduced all cause
child mortality by 17% and the incidence of uncomplicated
P. falciparum malaria by almost half16. However, there is concern
that the effectiveness of LLINs may be diminishing due to wide-
spread resistance to pyrethroids which until recently were the only
class of insecticides approved for LLINs. Similar to many other
African countries, high-level resistance to pyrethroids among the
principle Anopheles vectors has been reported recently throughout
Uganda17–19. In addition, behavioral changes in vector biting
activity following the introduction of LLINs have been reported



































Baseline 9 14,015 3766 (26.9) 3735 (99.2) 2450 (65.6) 923 (24.7) 932 104
Evaluation 25 46,850 21,245 (45.3) 18,185 (85.6) 17,210 (94.6) 14,200 (78.0) 16,699 668
Aduku HCIV
(Kwania)
Baseline 12 23,899 13,425 (56.2) 13,407 (99.9) 955 (7.1) 3189 (23.8) 3193 266
Evaluation 32 57,470 30,035 (52.2) 25,896 (86.2) 10,731 (41.4) 13,537 (52.3) 15,717 491
Anyeke
HCIV (Oyam)
Baseline 8 15,859 3514 (22.2) 2627 (74.8) 2604 (99.1) 680 (25.9) 918 115




Fig. 3 Predicted case counts and adjusted incidence rate ratios (IRR) from multilevel negative binomial model assessing the impact of withdrawing
indoor residual spraying (IRS) after 5 years of sustained use. The blue shaded region on the left represents the 95% confidence interval around the mean
predicted case counts across sites from the adjusted regression model. Gray lines represent observed monthly case counts from individual sites. On the
right, vertical bars represent the 95% confidence interval around the adjusted IRR (the measure of center for the error bars).
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which could present new challenges for malaria control20–22.
Finally, the effectiveness of LLINs may be further compromised by
poor adherence and waning coverage in the setting of free dis-
tribution campaigns done intermittently. In Uganda, less than
18% of households reported adequate coverage (defined as at least
one LLIN per two residents) 3 years after the 2013–14 distribution
campaign23 and adequate coverage decreased from 71% to 51%
between 6 and 18 months following the 2017–18 distribution
campaign24. Although the World Health Organization recom-
mends mass distribution campaigns every 3 years, mounting
evidence suggests that LLINs should be distributed more fre-
quently to sustain high coverage25–31.
Given concerns about the current effectiveness of pyrethroid-
based LLINs and the persistently high burden of malaria despite
aggressive scale-up of LLINs in countries like Uganda, addi-
tional malaria control measures are needed. IRS is an attractive
option. Historically, IRS programs were used to dramatically
reduce and even eliminate malaria in many parts of the world.
Thus, while there is some evidence for the impact of IRS in the
absence of LLINs32, it is surprising that the evidence base from
contemporary controlled trials on the impact of adding IRS to
LLINs for vector control is limited. A recent systematic review of
cluster randomized controlled trials conducted in sub-Saharan
Africa since 2008, reported that adding IRS using a “pyrethroid-
like” insecticide to LLINs did not provide any benefits, while
adding IRS with a “non-pyrethroid-like” insecticide produced
mixed results5. Among the four trials comparing IRS plus
LLINs with LLINs alone, three evaluated IRS with a carbamate
(bendiocarb) and one evaluated a long-lasting organophosphate,
pirimiphos-methyl (Actellic 300CS®)33–36. Only two trials (both
using bendiocarb) assessed malaria incidence; one from Sudan
found a 35% reduction when adding IRS to LLINs34, while
another from Benin found no benefit of adding IRS33. All four
trials assessed parasite prevalence, with an overall non-
significant trend towards a lower prevalence when adding IRS
to LLINs (RR= 0.67, 95% CI 0.35–1.28)5. However, when the
analyses were restricted to include only the two studies with
LLIN usage over 50%, adding IRS reduced parasite prevalence
by over 50% (RR= 0.47, 95% CI 0.33–0.67)5. Of note, none of
the trials that evaluated the impact of adding IRS with a “non-
pyrethroid-like” insecticide assessed outcomes beyond 2 years.
More recently, a number of observational studies have reported
Fig. 4 Predicted case counts and adjusted incidence rate ratios (IRR) from multilevel negative binomial model assessing the impact of restarting
indoor residual spraying (IRS) with a single round. The blue shaded region on the left represents the 95% confidence interval around the mean predicted
case counts across sites from the adjusted regression model. Gray lines represent observed monthly case counts from individual sites. On the right, vertical
bars represent the 95% confidence interval around the adjusted IRR (the measure of center for the error bars).


































Baseline 12 18,361 10,247 (55.8) 8161 (79.6) 7663 (93.9) 6069 (74.4) 7740 645
Evaluation 34 54,826 30,973 (56.5) 30,674 (99.0) 29,064 (94.8) 22,097 (72.0) 22,308 656
Aduku HCIV
(Kwania)
Baseline 12 25,439 14,912 (58.6) 11,944 (80.1) 4854 (40.6) 6559 (54.9) 8009 667
Evaluation 31 65,379 32,260 (49.3) 31,337 (97.1) 20,385 (65.1) 15,201 (48.5) 15,534 501
Anyeke
HCIV (Oyam)
Baseline 12 30,447 15,873 (52.1) 11,324 (71.3) 8628 (76.2) 7947 (70.2) 11,018 918
Evaluation 34 70,149 33,618 (47.9) 32,522 (96.7) 31,208 (96.0) 21,799 (67.0) 22,375 658
Awach
HCIV (Gulu)
Baseline 12 27,375 16,788 (61.3) 15,124 (90.1) 14,932 (98.7) 11,293 (74.7) 12,558 1047
Evaluation 30 69,375 36,760 (53.0) 35,189 (95.7) 34,070 (96.8) 21,879 (62.2) 22,851 762
Lalogi HCIV
(Omoro)
Baseline 12 39,517 24,235 (61.3) 23,959 (98.9) 23,951 (99.9) 17,000 (71.0) 17,202 1,434
Evaluation 31 72,449 41,846 (57.8) 41,668 (99.6) 40,804 (97.9) 22,986 (55.2) 23,060 744
Patongo HCIII
(Agago)
Baseline 12 21,745 13,482 (62.0) 13,244 (98.2) 12,938 (97.7) 10,032 (75.7) 10,142 845
Evaluation 34 54,486 34,482 (63.3) 33,797 (98.0) 32,176 (95.2) 17,231 (51.0) 17,440 513
Atiak HCIV
(Amuru)
Baseline 12 33,077 22,250 (67.3) 19,224 (86.4) 19,151 (99.6) 16,450 (85.6) 19,044 1,587
Evaluation 34 60,750 31,650 (52.1) 30,754 (97.2) 30,541 (99.3) 19,766 (64.3) 20,325 598
Padibe HCIV
(Lamwo)
Baseline 12 15,967 10,212 (64.0) 10,096 (98.9) 10,089 (99.9) 8171 (80.9) 10,089 841




Baseline 12 20,291 16,969 (83.6) 15,991 (94.2) 14,918 (93.3) 10,049 (62.8) 10,722 894
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benefits of using IRS with pirimiphos-methyl (Actellic 300CS®).
In the Mopti Region of Mali, delivery of a single round of IRS
with Actellic 300CS® was associated with a 42% decrease in the
peak incidence of laboratory-confirmed malaria cases reported
at public health facilities37. In the Koulikoro Region of Mali,
villages that received a single round of IRS with Actellic 300CS®
combined with LLINs observed a greater than 50% decrease in
the incidence of malaria compared to villages that only received
LLINs38. In the Northern Region of Ghana, districts that
received IRS with Actellic 300CS® reported 26–58% fewer cases
of laboratory-confirmed malaria cases reported at public health
facilities over a 2-year period, compared to districts that did not
receive IRS39. In Northern Zambia, implementation of IRS with
Actellic 300CS® targeting only high burden areas over a 3 year
period was associated with a 25% decline in parasite prevalence
during the rainy season, but no decline during the dry season40.
In Western Kenya, the introduction of a single round of IRS
with Actellic 300CS® was associated with a 44–65% decrease in
district level malaria case counts over a 10 month period com-
pared to pre-IRS levels41. In addition, several recent reports
have documented dramatic resurgences of malaria following the
withdrawal of IRS with bendiocarb in Benin42, and the with-
drawal of IRS with Actellic 300CS® in Mali and Ghana37,39.
The results from this study provides additional support for the
critical role IRS can play in reducing the burden of malaria in
African countries with high LLINs coverage. A strength of the
study was its use of a large, rigorously collected dataset. Data were
collected over nearly 7 years through an enhanced health facility-
based surveillance system covering 14 districts in Uganda where
IRS was being withdrawn, re-started, and initiated. This enhanced
surveillance system facilitated laboratory testing and provided
prospectively collected, individual-level data, allowing for ana-
lyses of quantitative changes in laboratory-confirmed cases of
malaria over time, controlling for temporal changes in rainfall,
seasonal effects, diagnostic practices, and health seeking behavior.
Previous work by our group documented a marked decrease in
malaria TPRs after 4 years of sustained IRS with bendiocarb in
one district of Northern Uganda followed by a rapid resurgence
over an 18-month period after IRS was withdrawn11. In this study
we expand on these findings by including data from three districts
and covering a 31-month period following the withdrawal of IRS.
We were able to quantify more than a fivefold increase in malaria
cases which was sustained over the 10–31 months following the
withdrawal of IRS. This marked resurgence occurred despite the
fact the first universal LLIN distribution campaign was timed to
occur right after IRS was withdrawn. Given the dramatic nature
of the resurgence, the Ugandan government was able to procure
funding for a single round of IRS with Actellic 300CS® ~3 years
after IRS was withdrawn in 10 districts of Northern Uganda. In
this study, we assessed the impact of this single round in nine of
these districts. This single round was associated with over a
fivefold decrease in malaria cases after 8–12 months, with malaria
cases returning to pre-IRS levels after almost 2 years. These data
suggest that IRS with longer-acting formulations such as Actellic
Fig. 5 Predicted case counts and adjusted incidence rate ratios (IRR) from multilevel negative binomial model assessing the impact of initiating and
sustaining indoor residual spraying (IRS). The blue shaded region on the left represents the 95% confidence interval around the mean predicted case
counts across sites from the adjusted regression model. Gray lines represent observed monthly case counts from individual sites. On the right, vertical bars
represent the 95% confidence interval around the adjusted IRR (the measure of center for the error bars).
Table 3 Summary statistics from health-facility based surveillance sites where IRSa was initiated and sustained.




























Baseline 12 20,828 13,251 (63.6) 13,096 (98.8) 760 (5.8) 3298 (25.2) 3337 278
Evaluation 59 97,012 36,308 (37.4) 36,069 (99.3) 13,129 (36.4) 4984 (13.8) 5022 85
Amolatar HCIV
(Amolatar)
Baseline 12 19,552 8547 (43.7) 6512 (76.2) 5923 (91.0) 3701 (56.8) 4845 404
Evaluation 59 89,779 24,889 (27.8) 21,849 (87.9) 19,459 (89.1) 4822 (22.1) 5854 99
Dokolo HCIV
(Dokolo)
Baseline 12 25,570 12,854 (50.3) 8875 (69.0) 8212 (92.5) 5211 (58.7) 7889 657
Evaluation 59 129,245 46,428 (35.9) 44,972 (96.9) 42,259 (94.0) 10,210 (22.7) 10,761 183
Orum HCIV
(Otuke)
Baseline 11 16,120 9324 (57.8) 8929 (95.8) 3990 (44.7) 5974 (66.9) 6236 567
Evaluation 59 65,036 37,430 (57.6) 36,371 (97.2) 19,536 (53.7) 16,481 (45.3) 17,069 289
Alebtong HCIV
(Alebtong)
Baseline 8 15,359 6694 (43.6) 4789 (71.5) 4620 (96.5) 3209 (67.0) 4317 540
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300CS® administered every 2 years could be considered as a
strategy for mitigating the risk of resurgence following sustained
IRS and/or enabling countries to expand coverage when resources
are limited, but formal assessment and a cost-effectiveness ana-
lyses are needed. This study also evaluated the impact of 5 years
of sustained IRS in five districts of Eastern Uganda, starting first
with bendiocarb and then switching to Actellic 300CS® after
18 months. Rounds of IRS were initially associated with marked
decreases in malaria cases followed by peaks before subsequent
rounds until the fourth and fifth years after IRS was initiated
when there was a sustained decrease of almost sevenfold com-
pared to pre-IRS level. Given the before-and-after nature of our
study design, it is not clear whether the maximum sustained
benefits of IRS seen after 4–5 years were due to the cumulative
effect of multiple rounds of IRS, the switch from bendiocarb to
Actellic 300CS®, improvements in implementation (although
campaigns occurred regularly and coverage was universally high
across rounds, see Supplementary Table 4), the second universal
LLIN distribution campaign which occurred in this area in 2017,
and/or other factors.
This study had several limitations. First, we used an observa-
tional study design, with measures of impact based on compar-
isons made before-and-after key changes in IRS policy. Although
cluster randomized controlled trials are the gold standard study
design for estimating the impact of IRS, it could be argued that
withholding IRS would be unethical, given what is known about
its impact in Uganda. Second, our estimates of impact could have
been confounded by secular trends in factors not accounted for in
our analyses. However, we feel that our overall conclusions are
robust given the large amount of data available from multiple
sites over an extended period with multiple complementary
objectives providing consistent findings. Third, we could not
assess the impact of IRS independent of LLIN use and did not
have access to measures of IRS or LLIN coverage from our study
populations. It is possible that some of the impacts we observed
were from LLIN distributions in combination with IRS cam-
paigns. However, we were able to provide a “real world” assess-
ment of IRS in a setting where LLIN use is strongly supported by
repeated universal distribution campaigns that are becoming
increasingly common in sub-Saharan Africa. Similarly, we cannot
draw conclusions on the impact of different IRS compounds
given all sites received the same formulations consecutively. The
results from Objective 3 indicate that malaria incidence dropped
substantially in the years that districts stopped receiving bend-
iocarb and began receiving Actellic 300CS®. However, we cannot
conclude whether this reduction was a result of this change or
rather the cumulative impact of sustained IRS campaigns, as it
has been suggested that in very high transmission settings, several
years of IRS may be needed to maximize impact on measures of
morbidity.43,44 Finally, our study outcome was limited to case
counts of laboratory-confirmed malaria captured at health facil-
ities. Thus, we were unable to measure the impact of IRS on other
important indicators such as measures of vector distribution,
parasite prevalence, or mortality.
There is a growing body of evidence that combining LLINs
with IRS using “non-pyrethroid-like” insecticides, especially the
long acting organophosphate Actellic 300CS®, is highly effective
at reducing the burden of malaria in Uganda, and elsewhere in
Africa. Despite these encouraging findings, IRS coverage in Africa
has been moving in the wrong direction. The proportion of those
at risk protected by IRS in Africa peaked at just over 10% in 2010.
However, the spread of pyrethroid resistance has led many con-
trol programs to switch to more expensive formulations resulting
in a 53% decrease in the number of houses sprayed between years
of peak coverage and 2015 across 18 countries supported by the
US President’s Malaria Initiative45 and an overall reduction in the
proportion protected by IRS in Africa to less than 2% in 20192.
Given the lack of recent progress in reducing the global burden of
malaria coupled with challenges in funding, renewed commit-
ments are needed to address the “high burden to high impact”
approach now being advocated by the World Health
Organization2. IRS is a widely available tool that could be scaled
up, however demands currently exceed the availability of
resources. Additional work is needed to optimize the use of IRS,
prevent further spread of insecticide resistance, and better eval-
uate the cost-effectiveness of IRS in the context of other control
interventions.
Methods
Health-facility based surveillance. Enhanced malaria surveillance was established
by UMSP in 200646. UMSP operates Malaria Reference Centers (MRCs) at 70 level
III/IV public health facilities across Uganda. At each MRC, individual-level data
from standardized registers for all patients presenting to the outpatient departments
are entered into a Microsoft Access (v16.0) database by on-site data entry officers.
Variables include patient demographics, results of laboratory testing for malaria
(rapid diagnostic test [RDT] or microscopy), diagnoses given, and treatments
prescribed. Emphasis is placed on ensuring that patients with suspected malaria
undergo testing, by either RDT or microscopy.
This study utilized data from 14 MRCs located in districts that either previously
had IRS or have ongoing IRS campaigns. We estimated the impact of withdrawing
IRS using data from three sites in Northern Uganda that had at least 6 months of
data preceding the final round of IRS administered in 2014. To estimate the impact
of restarting IRS with a single round administered in 2017, we used data from nine
sites in Northern Uganda. To estimate the impact of sustained IRS over 5 years, we
used data from five sites in Eastern Uganda where IRS had been implemented since
2014–15. For all analyses, we accessed raw, individual-level data, and aggregated to
monthly-level data.
Measures. The exposure was specified as an indicator variable for each month
since IRS was withdrawn or initiated relative to a baseline period (Fig. 1 and
Supplementary Fig. 1). All baseline periods were defined as the 12 month period
immediately preceding the intervention (or stopping the intervention) pending
data availability. If fewer than 12 months of baseline data were available, we
included the maximum amount of time available for sites that had at least
6 months of data before the evaluation period. We also fit separate models with
categorical exposure variables divided into distinct periods of months. To deter-
mine the impact of withdrawing IRS after at least 5 years of sustained use, the
baseline period was defined as the year leading up to the final round of IRS, and the
evaluation period lasted through 2016, prior to when an additional round of IRS
was implemented. In order to determine the impact of restarting IRS with a single
round of IRS, the baseline period was defined as 1 year prior to the single round of
IRS and the evaluation period went through December 2019. To determine the
impact of initiating and sustaining IRS, the baseline period was the year prior to
IRS initiation, and the evaluation period lasted through December 2019.
The primary outcome was the monthly count of laboratory-confirmed malaria
cases at each MRC. The case count was corrected for testing rates by multiplying
the number of individuals with suspected malaria but not tested each month by the
TPR (the number who tested positive divided by the total number tested) for that
month and adding the result to the number of laboratory-confirmed positive cases.
As a sensitivity analysis, we re-specified the models including only laboratory-
confirmed case counts as the outcome.
We adjusted for time-varying variables that impact malaria burden and malaria
case detection at the health facility. These variables included monthly rainfall at the
health facility lagged by 1 month extracted from the Climate Hazards Infrared
Precipitation with Stations database47, indicator variables for month of the year (to
adjust for seasonal effects), the proportion of tests that were RDTs in that month
(vs. microscopy), and the number of individuals who attended the health facility
but were not suspected of having malaria in that month (to adjust for potential
changes in care-seeking behaviors over time).
Statistical analysis. For each objective, we specified mixed effects negative
binomial regression models with random intercepts for health facility. Coefficients
for the exposure variable were exponentiated to represent the incidence rate ratio
(IRR) comparing the incidence of malaria in the month of interest relative to the
baseline period. This method assumes that the underlying population has remained
constant over the study period. All analyses were carried out in R v3.6 and
Stata v14.
Ethics Approval and consent to participate. Ethical approval for study proce-
dures and data collection was provided by ethics committees of University of
California San Francisco (REF 250046), the School of Medicine College of Health
Sciences at Makerere University (REF 2019-087), and Uganda National Council of
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Science and Technology (REF HS 2659). Written informed consent was not
required by the ethical review committees due to the routine, de-identified nature
of the data.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analysed during the current study are available in
github with the identifier https://doi.org/10.5281/zenodo.4625804. To obtain raw data for
these analyses, please contact the corresponding author. Precipitation data was accessed
through the Climate Hazards Infrared Precipitations with Stations database, available
publicly at https://data.chc.ucsb.edu/products/CHIRPS-2.0/48
Code availability
Computing code is available at https://doi.org/10.5281/zenodo.4625804
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